LataMed AI Corp. (OTC: LMED), a healthcare technology company focused on digital health and artificial intelligence solutions for Latin America, announced that its Venezuelan subsidiary, LATAMEDAI VE, will participate in the 'Artificial Intelligence & Health Markets 2026' conference scheduled for August 13-14, 2026, at Universidad Santa Maria in Caracas. The event aims to bring together students, faculty, and professionals from systems engineering and healthcare disciplines, including pharmacy, dentistry, and laboratory sciences, to explore practical applications of AI and automation.
Dr. Kevin Rodan Levy, CEO, and Carlos Pena, CFO, will represent LataMed AI. Their presentation will address the evolving role of AI in healthcare, systems engineering, digital infrastructure, and professional decision-making. The company plans to discuss how AI-supported tools can assist healthcare professionals in medical-data evaluation, clinical workflows, and operational decision-making, as well as how automation may enhance the organization, reliability, and efficiency of technology systems in healthcare and other complex environments.
A key focus will be the importance of qualified professional oversight when implementing AI. LataMed AI emphasizes that its technologies are designed to augment human capabilities and support informed decision-making, not replace the judgment of healthcare professionals, engineers, laboratory personnel, or other qualified individuals. Additional topics will include integrating AI and automation into existing systems, responsible data use, privacy and information security, operational risk management, and practical considerations in developing and deploying healthcare technology.
The company also intends to discuss its healthcare technology ecosystem, including the development of CardioAI, PulmoAI, and NeuroAI—AI-supported platforms designed to assist professionals in evaluating cardiovascular, pulmonary, and neurological health information, subject to ongoing development, testing, and regulatory approvals.
Dr. Levy remarked, "Artificial Intelligence & Health Markets 2026 provides an important opportunity to engage directly with students, educators, and future professionals who will help shape the responsible use of artificial intelligence in healthcare and systems engineering. Our objective is to share practical perspectives on how intelligent technologies can support professional decision-making, improve digital workflows, and contribute to the continued development of healthcare infrastructure in Latin America."
Management believes that engagement with universities can increase awareness of emerging healthcare technologies, foster responsible discussions about AI, and strengthen relationships with future professionals. The company also views this participation as a chance to understand the perspectives of students, educators, researchers, and technical professionals as it continues developing digital health solutions for the Latin American market.
This initiative aligns with LataMed AI's broader strategy of supporting education, professional collaboration, and the responsible adoption of digital healthcare infrastructure throughout the region. The company plans to evaluate further opportunities to participate in academic, healthcare, and technology forums that align with its objectives.
Importantly, participation in the conference does not constitute an endorsement of LataMed AI or its technologies by Universidad Santa Maria, and the event does not guarantee future collaborations, regulatory approvals, revenue, or other financial benefits.
The announcement underscores the growing intersection of AI, healthcare, and systems engineering, and the importance of educational forums in shaping the responsible integration of technology. For leaders in business and technology, this development highlights LataMed AI's commitment to engaging with academic communities to foster innovation and practical AI applications in healthcare settings.
For more information, visit https://latamed.ai or review the company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
